首页 > 最新文献

Indian Journal of Hematology and Blood Transfusion最新文献

英文 中文
Advanced Lymphomatoid Granulomatosis Involving the Central Nervous System and Lung Parenchyma Presenting with Speech and Gait Disturbances 累及中枢神经系统和肺实质并伴有言语和步态障碍的晚期淋巴样肉芽肿病
IF 0.9 4区 医学 Pub Date : 2024-09-05 DOI: 10.1007/s12288-024-01860-5
Sarthak Wadhera, Rudra Narayan Swain, Shashikant Saini, Charanpreet Singh, Arihant Jain, Amanjit Bal, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra
{"title":"Advanced Lymphomatoid Granulomatosis Involving the Central Nervous System and Lung Parenchyma Presenting with Speech and Gait Disturbances","authors":"Sarthak Wadhera, Rudra Narayan Swain, Shashikant Saini, Charanpreet Singh, Arihant Jain, Amanjit Bal, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra","doi":"10.1007/s12288-024-01860-5","DOIUrl":"https://doi.org/10.1007/s12288-024-01860-5","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"10 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Osteonecrosis in Survivors of Childhood Acute Lymphoblastic Leukaemia of Indian Ethnicity Treated with BFM Protocol 接受 BFM 方案治疗的印度裔儿童急性淋巴细胞白血病幸存者的骨坏死患病率
IF 0.9 4区 医学 Pub Date : 2024-09-05 DOI: 10.1007/s12288-024-01861-4
Sanjeev Khera, Shijith KP, Rajan Kapoor, Rajiv Kumar, Somali Pattanayak

There is paucity of data from low-middle income countries (LMIC) on osteonecrosis (ON) in survivors of childhood acute lymphoblastic leukaemia (cALL-survivors). We conducted this study to estimate prevalence of ON in cALL-survivors of Indian ethnicity and factors affecting it. This cross-sectional study enrolled cALL-survivors post completion of treatment. ON was estimated using magnetic resonance imaging of hip joint. Demographic, anthropometric, therapy/disease-related and biochemical/endocrine factors affecting calcium homeostasis were studied in two groups: with and without ON. Total of 61 out of enrolled 87 cALL-survivors with median age 118 months (range:84–283) were analysed after median 12 months (range:1–113) post completion of therapy. Two-third of the cohort was male and 41% were pubertal. 5/61 (8.2%) were found to have asymptomatic and non-traumatic ON. Three ON were grade II and two were grade III as per Niinimaki radiological classification. Cumulative doses (CD) of dexamethasone, glucocorticoids (GCs), L-asparginase, anthracycline and low serum vit D levels were associated with ON. Other demographic factors including age at diagnosis > 10 year, disease-related, therapy-related factors including cranial irradiation and biochemical/endocrine factors were not associated with ON. The median CD of dexamethasone (p = 0.004) and GCs (p = 0.008) were significantly high in group with ON. Median CD of methotrexate(p = 0.051), anthracycline(p = 0.058) and serum vit D levels(p = 0.054) along with serum alkaline phosphatase levels(p = 0.06) had a trend towards significance but were not statistically significant in ON group. Prevalence of ON of hip in our cohort of cALL-survivors was 8.2%. Higher CD of GCs appeared to be the most significant risk factor associated with ON in our cohort.

来自中低收入国家(LMIC)的有关儿童急性淋巴细胞白血病(cALL-survivors)幸存者骨坏死(ON)的数据很少。我们开展了这项研究,以估算印度裔儿童急性淋巴细胞白血病幸存者骨坏死的发病率及其影响因素。这项横断面研究招募了完成治疗后的 cALL 幸存者。通过髋关节磁共振成像对ON进行估计。研究了两组患者的人口统计学、人体测量、治疗/疾病相关因素以及影响钙平衡的生化/内分泌因素:有钙化和无钙化。在完成治疗后的中位 12 个月(范围:1-113)后,对 87 名 cALL 幸存者中的 61 人进行了分析,他们的中位年龄为 118 个月(范围:84-283)。其中三分之二为男性,41%处于青春期。5/61(8.2%)的患者被发现患有无症状和非创伤性ON。根据Niinimaki放射学分类,3例ON为II级,2例为III级。地塞米松、糖皮质激素(GCs)、L-天冬酰胺酶、蒽环类药物的累积剂量(CD)和低血清维生素D水平与ON有关。其他人口统计学因素,包括诊断时的年龄(10岁)、疾病相关因素、治疗相关因素(包括颅骨照射)以及生化/内分泌因素与ON无关。在ON组中,地塞米松(p = 0.004)和GCs(p = 0.008)的中位CD明显偏高。甲氨蝶呤(p = 0.051)、蒽环类药物(p = 0.058)和血清维生素D水平(p = 0.054)以及血清碱性磷酸酶水平(p = 0.06)的中位数CD在ON组有显着性趋势,但无统计学意义。在我们的 cALL 幸存者队列中,髋关节 ON 的发病率为 8.2%。在我们的队列中,较高的GCs CD似乎是与ON相关的最重要的风险因素。
{"title":"Prevalence of Osteonecrosis in Survivors of Childhood Acute Lymphoblastic Leukaemia of Indian Ethnicity Treated with BFM Protocol","authors":"Sanjeev Khera, Shijith KP, Rajan Kapoor, Rajiv Kumar, Somali Pattanayak","doi":"10.1007/s12288-024-01861-4","DOIUrl":"https://doi.org/10.1007/s12288-024-01861-4","url":null,"abstract":"<p>There is paucity of data from low-middle income countries (LMIC) on osteonecrosis (ON) in survivors of childhood acute lymphoblastic leukaemia (cALL-survivors). We conducted this study to estimate prevalence of ON in cALL-survivors of Indian ethnicity and factors affecting it. This cross-sectional study enrolled cALL-survivors post completion of treatment. ON was estimated using magnetic resonance imaging of hip joint. Demographic, anthropometric, therapy/disease-related and biochemical/endocrine factors affecting calcium homeostasis were studied in two groups: with and without ON. Total of 61 out of enrolled 87 cALL-survivors with median age 118 months (range:84–283) were analysed after median 12 months (range:1–113) post completion of therapy. Two-third of the cohort was male and 41% were pubertal. 5/61 (8.2%) were found to have asymptomatic and non-traumatic ON. Three ON were grade II and two were grade III as per Niinimaki radiological classification. Cumulative doses (CD) of dexamethasone, glucocorticoids (GCs), L-asparginase, anthracycline and low serum vit D levels were associated with ON. Other demographic factors including age at diagnosis &gt; 10 year, disease-related, therapy-related factors including cranial irradiation and biochemical/endocrine factors were not associated with ON. The median CD of dexamethasone (<i>p</i> = 0.004) and GCs (<i>p</i> = 0.008) were significantly high in group with ON. Median CD of methotrexate(<i>p</i> = 0.051), anthracycline(<i>p</i> = 0.058) and serum vit D levels(<i>p</i> = 0.054) along with serum alkaline phosphatase levels(<i>p</i> = 0.06) had a trend towards significance but were not statistically significant in ON group. Prevalence of ON of hip in our cohort of cALL-survivors was 8.2%. Higher CD of GCs appeared to be the most significant risk factor associated with ON in our cohort.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"128 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Different Doses of Oral Iron on Hepcidin and Treatment Response in Iron Deficiency Anemia 不同剂量口服铁剂对缺铁性贫血患者肝素和治疗反应的影响
IF 0.9 4区 医学 Pub Date : 2024-09-02 DOI: 10.1007/s12288-024-01844-5
Ozlem Beyler, Cengiz Demir, Vehbi Demircan, Murat Kacmaz

Introduction

Iron deficiency anemia (IDA) is a common health problem. The hepcidin hormone is the main regulator of systemic iron balance. The body responds to IDA by decreasing hepcidin. This study investigated how different iron supplementation regimens affect hepcidin levels in women with IDA. 87 female participants aged 18–45 years with hemoglobin < 10 g/dL and serum ferritin < 20 ng/ml were assigned to receive iron therapy every other day, once daily, or twice daily. Hemogram, serum iron, serum iron binding capacity, ferritin, hepcidin, and C-reactive protein values were measured at baseline and on the 15th and 90th days of treatment in all groups. On the seventh day, no significant difference was found between the once-daily and twice-daily groups (p = 0.42) in reticulocyte counts. By the 15th day, hemoglobin and MCV levels showed significant improvement in the twice-daily group compared to the other groups (p < 0.01). At the third month, ferritin levels were significantly higher in the twice-daily group compared to the every-other-day and once-daily groups (p = 0.03). No significant differences were observed in hepcidin levels at three months across all groups. The study concludes that twice-daily iron supplementation results in the most significant hematological improvements but with increased gastrointestinal side effects. These findings underscore the importance of tailoring iron dosing schedules to individual patient needs. In cases where rapid haemoglobin response is required, twice-daily dosing may provide superior results. Conversely, once-daily dosing may be preferred if tolerable anemia can be maintained. Every other day dosing, although associated with fewer side effects and better tolerability, may not provide adequate support for erythropoiesis.

导言缺铁性贫血(IDA)是一种常见的健康问题。血红素激素是全身铁平衡的主要调节器。人体通过降低血红素来应对缺铁性贫血。本研究调查了不同的补铁方案如何影响患有 IDA 的女性体内的肝素水平。87名年龄在18-45岁之间、血红蛋白< 10 g/dL、血清铁蛋白< 20 ng/ml的女性参与者被分配接受铁剂治疗,治疗方案为隔日一次、每日一次或每日两次。在基线以及治疗的第 15 天和第 90 天,测量了各组的血型图、血清铁、血清铁结合能力、铁蛋白、肝素和 C 反应蛋白值。在第七天,每日一次组和每日两次组的网织红细胞计数无明显差异(p = 0.42)。到第 15 天,每日两次组的血红蛋白和 MCV 水平与其他组相比有显著改善(p < 0.01)。第三个月时,每日两次组的铁蛋白水平明显高于隔日一次组和每日一次组(p = 0.03)。所有组别在三个月时的血红素水平均无明显差异。研究得出结论,每日两次补充铁剂可使血液学指标得到最明显的改善,但胃肠道副作用也会增加。这些发现强调了根据患者个体需求制定铁剂剂量计划的重要性。在需要快速血红蛋白反应的病例中,每日两次给药可能会取得更好的效果。相反,如果能维持可耐受的贫血,则可选择每日一次给药。隔天给药虽然副作用较少且耐受性较好,但可能无法为红细胞生成提供足够的支持。
{"title":"Effects of Different Doses of Oral Iron on Hepcidin and Treatment Response in Iron Deficiency Anemia","authors":"Ozlem Beyler, Cengiz Demir, Vehbi Demircan, Murat Kacmaz","doi":"10.1007/s12288-024-01844-5","DOIUrl":"https://doi.org/10.1007/s12288-024-01844-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Iron deficiency anemia (IDA) is a common health problem. The hepcidin hormone is the main regulator of systemic iron balance. The body responds to IDA by decreasing hepcidin. This study investigated how different iron supplementation regimens affect hepcidin levels in women with IDA. 87 female participants aged 18–45 years with hemoglobin &lt; 10 g/dL and serum ferritin &lt; 20 ng/ml were assigned to receive iron therapy every other day, once daily, or twice daily. Hemogram, serum iron, serum iron binding capacity, ferritin, hepcidin, and C-reactive protein values were measured at baseline and on the 15th and 90th days of treatment in all groups. On the seventh day, no significant difference was found between the once-daily and twice-daily groups (<i>p</i> = 0.42) in reticulocyte counts. By the 15th day, hemoglobin and MCV levels showed significant improvement in the twice-daily group compared to the other groups (<i>p</i> &lt; 0.01). At the third month, ferritin levels were significantly higher in the twice-daily group compared to the every-other-day and once-daily groups (<i>p</i> = 0.03). No significant differences were observed in hepcidin levels at three months across all groups. The study concludes that twice-daily iron supplementation results in the most significant hematological improvements but with increased gastrointestinal side effects. These findings underscore the importance of tailoring iron dosing schedules to individual patient needs. In cases where rapid haemoglobin response is required, twice-daily dosing may provide superior results. Conversely, once-daily dosing may be preferred if tolerable anemia can be maintained. Every other day dosing, although associated with fewer side effects and better tolerability, may not provide adequate support for erythropoiesis.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"5 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Physical Activity and Fear of Movement in Patients with Hemophilic Arthropathy 血友病关节病患者的体育锻炼与运动恐惧之间的关系
IF 0.9 4区 医学 Pub Date : 2024-09-01 DOI: 10.1007/s12288-024-01856-1
Dimple Choudhry, Malika, Sudhir Kumar Atri, Pankaj Kumar, Poonam Dhankher

Physical activity plays an important role in Hemophilic patients it provides multiple benefits to patients but in Hemophilia, patients instead of doing physical activity fear to do movement or any kind of exercise. Some associated factors that can prevent the patient from doing movement are pain, fear, or Kinesio-phobia and arthropathy. So, the study aimed to find the association between physical activity and fear of movement in Hemophilic patients. This cross-sectional study was done on 30 Hemophilics. All Hemophilic patients were males and between the age group of 18–60 years (mean = 29.36 ± 10.84). Data about physical activity and Kinesio-phobia was taken. The Tampa scale of Kinesio-phobia was used to determine the fear of movement. Physical activity was also determined. The results were analyzed by using the Mann–Whitney U test. There was no significant statistical correlation between physical activity and fear of movement in patients with mild and moderate hemophilia but there was a significant in severe hemophilic patients. High Kinesio-phobia levels (TSK score of ≥ 37) were present in 90% of patients. There is a higher rate of Kinesio-phobia in adult patients of Hemophilia so, education should be provided to patients about safe and fearless physical activity.

体育锻炼在血友病患者中扮演着重要的角色,它能为患者带来多种益处,但对于血友病患者来说,与其进行体育锻炼,不如说他们害怕运动或任何形式的锻炼。妨碍患者进行运动的一些相关因素包括疼痛、恐惧、运动恐惧症和关节病。因此,本研究旨在找出血友病患者的体力活动与运动恐惧之间的关联。这项横断面研究的对象是 30 名血友病患者。所有血友病患者均为男性,年龄在 18-60 岁之间(平均 = 29.36 ± 10.84)。研究人员采集了患者的运动量和运动恐惧症数据。运动恐惧症坦帕量表用于确定患者对运动的恐惧程度。同时还测定了运动量。结果采用曼-惠特尼 U 检验进行分析。在轻度和中度血友病患者中,体力活动与运动恐惧之间没有明显的统计学相关性,但在重度血友病患者中却有明显的相关性。90% 的患者存在高度运动恐惧(TSK 评分≥ 37 分)。成年血友病患者的运动恐怖症发病率较高,因此应向患者提供有关安全和无恐惧体育活动的教育。
{"title":"Association Between Physical Activity and Fear of Movement in Patients with Hemophilic Arthropathy","authors":"Dimple Choudhry, Malika, Sudhir Kumar Atri, Pankaj Kumar, Poonam Dhankher","doi":"10.1007/s12288-024-01856-1","DOIUrl":"https://doi.org/10.1007/s12288-024-01856-1","url":null,"abstract":"<p>Physical activity plays an important role in Hemophilic patients it provides multiple benefits to patients but in Hemophilia, patients instead of doing physical activity fear to do movement or any kind of exercise. Some associated factors that can prevent the patient from doing movement are pain, fear, or Kinesio-phobia and arthropathy. So, the study aimed to find the association between physical activity and fear of movement in Hemophilic patients. This cross-sectional study was done on 30 Hemophilics. All Hemophilic patients were males and between the age group of 18–60 years (mean = 29.36 ± 10.84). Data about physical activity and Kinesio-phobia was taken. The Tampa scale of Kinesio-phobia was used to determine the fear of movement. Physical activity was also determined. The results were analyzed by using the Mann–Whitney U test. There was no significant statistical correlation between physical activity and fear of movement in patients with mild and moderate hemophilia but there was a significant in severe hemophilic patients. High Kinesio-phobia levels (TSK score of ≥ 37) were present in 90% of patients. There is a higher rate of Kinesio-phobia in adult patients of Hemophilia so, education should be provided to patients about safe and fearless physical activity.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"23 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peaks and Distortions: Evaluation of Irregularities in Capillary Serum Protein Electrophoresis-An Institutional Experience of 980 Cases From Bihar 峰值和失真:毛细管血清蛋白电泳中不规则现象的评估--来自比哈尔邦 980 个病例的机构经验
IF 0.9 4区 医学 Pub Date : 2024-08-29 DOI: 10.1007/s12288-024-01853-4
Iffat Jamal, Shuchismita, Ravi Bhushan Raman, Vijayanand Choudhary

Capillary zone electrophoresis (CZE) is an easy to perform technique encompassing a wide range of clinical applications ranging from inflammatory, renal, hepatic, neurological disorders as well as hematological malignancies like Plasma cell neoplasms. The objectives of the study are to explore various patterns of serum protein abnormalities in different medical diseases ranging from systemic disorders to hematological malignancies coming to our institute and to correlate these electrophoretic abnormalities with clinic-hematological and biochemical parameters. The present study was conducted in the Department of Hematology of a tertiary care institute over a period of 20 months. Altogether 980 samples were received for serum protein electrophoresis (SPE) in clinically indicated cases. Detailed clinical history, hematological and biochemical reports were compiled and analyzed with SPE reports. SPE was performed by Minicap Flex piercing fully automated capillary electrophoresis system from Sebia France and results were interpreted. In the present study, out of 980 cases 630 (64.3%) were males and 350 (35.7%) were females with a M: F ratio of 1.9:1. Most of the cases were in the age group of 51–60 years (n-285, 47.4%) followed by 41–50 years (n = 188, 27%). The most common indication for SPE was Chronic kidney disease (CKD) that accounted for 50% of all cases, followed by Plasma cell neoplasms (40%). Acute kidney injury (AKI), nephrotic syndrome (NS), peripheral neuropathy, and unexplained anemia were the other indications. Most common SPE pattern obtained on CZE was that of polyclonal hypergammaglobulinemia accounting to 316 of all cases (32.2%), closely followed by 292 cases of chronic inflammatory pattern (29.7%). Distortion in gamma region was seen in 14.7% cases (145/980). A distinct M spike was seen in 57 cases (5.8%) suggesting a diagnosis of monoclonal gammopathy. A comprehensive look at all the protein fractions, their distortions and peaks along with clinico-biochemical and hematological correlation can help in reaching out to a correct diagnosis.

毛细管区带电泳(CZE)是一种易于操作的技术,临床应用范围广泛,包括炎症、肾脏、肝脏、神经系统疾病以及浆细胞肿瘤等血液恶性肿瘤。本研究的目的是探索本研究所收治的不同内科疾病(从全身性疾病到血液恶性肿瘤)中血清蛋白异常的各种模式,并将这些电泳异常与临床血液学和生化参数联系起来。本研究在一家三级医疗机构的血液科进行,历时 20 个月。共收到 980 份有临床指征病例的血清蛋白电泳(SPE)样本。详细的临床病史、血液学和生化报告与 SPE 报告一起汇编和分析。SPE 采用法国 Sebia 公司生产的 Minicap Flex 穿孔全自动毛细管电泳系统进行,并对结果进行解读。在本研究的 980 个病例中,630 例(64.3%)为男性,350 例(35.7%)为女性,男女比例为 1.9:1。大多数病例的年龄在 51-60 岁(285 人,占 47.4%),其次是 41-50 岁(188 人,占 27%)。最常见的 SPE 适应症是慢性肾病(CKD),占所有病例的 50%,其次是浆细胞肿瘤(40%)。急性肾损伤(AKI)、肾病综合征(NS)、周围神经病变和原因不明的贫血是其他适应症。CZE检查中最常见的SPE模式是多克隆高丙种球蛋白血症,占所有病例的316例(32.2%),紧随其后的是292例慢性炎症模式(29.7%)。14.7%的病例(145/980)出现伽马区畸变。在 57 个病例(5.8%)中出现了明显的 M 峰,提示诊断为单克隆性腺病。对所有蛋白质组分、其变形和峰值以及临床生化和血液学相关性进行全面检查有助于得出正确的诊断。
{"title":"Peaks and Distortions: Evaluation of Irregularities in Capillary Serum Protein Electrophoresis-An Institutional Experience of 980 Cases From Bihar","authors":"Iffat Jamal, Shuchismita, Ravi Bhushan Raman, Vijayanand Choudhary","doi":"10.1007/s12288-024-01853-4","DOIUrl":"https://doi.org/10.1007/s12288-024-01853-4","url":null,"abstract":"<p>Capillary zone electrophoresis (CZE) is an easy to perform technique encompassing a wide range of clinical applications ranging from inflammatory, renal, hepatic, neurological disorders as well as hematological malignancies like Plasma cell neoplasms. The objectives of the study are to explore various patterns of serum protein abnormalities in different medical diseases ranging from systemic disorders to hematological malignancies coming to our institute and to correlate these electrophoretic abnormalities with clinic-hematological and biochemical parameters. The present study was conducted in the Department of Hematology of a tertiary care institute over a period of 20 months. Altogether 980 samples were received for serum protein electrophoresis (SPE) in clinically indicated cases. Detailed clinical history, hematological and biochemical reports were compiled and analyzed with SPE reports. SPE was performed by Minicap Flex piercing fully automated capillary electrophoresis system from Sebia France and results were interpreted. In the present study, out of 980 cases 630 (64.3%) were males and 350 (35.7%) were females with a M: F ratio of 1.9:1. Most of the cases were in the age group of 51–60 years (n-285, 47.4%) followed by 41–50 years (n = 188, 27%). The most common indication for SPE was Chronic kidney disease (CKD) that accounted for 50% of all cases, followed by Plasma cell neoplasms (40%). Acute kidney injury (AKI), nephrotic syndrome (NS), peripheral neuropathy, and unexplained anemia were the other indications. Most common SPE pattern obtained on CZE was that of polyclonal hypergammaglobulinemia accounting to 316 of all cases (32.2%), closely followed by 292 cases of chronic inflammatory pattern (29.7%). Distortion in gamma region was seen in 14.7% cases (145/980). A distinct M spike was seen in 57 cases (5.8%) suggesting a diagnosis of monoclonal gammopathy. A comprehensive look at all the protein fractions, their distortions and peaks along with clinico-biochemical and hematological correlation can help in reaching out to a correct diagnosis.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"2 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142224733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laboratory Profile of Lupus Anticoagulant Positive Cases and its Association with Clinical Presentation- Experience from a Tertiary Care Centre in Southern India 狼疮抗凝物阳性病例的实验室概况及其与临床表现的关系--来自印度南部一家三级医疗中心的经验
IF 0.9 4区 医学 Pub Date : 2024-08-29 DOI: 10.1007/s12288-024-01851-6
Pranav Raghuram, Mithraa Devi Sekar, Lokeshwari Srinivasan, Prabhu Manivannan, Debdatta Basu, Rakhee Kar

Antiphospholipid syndrome (APS) is an autoimmune disease with specific clinical features and the presence of antiphospholipid antibodies (aPL) like anti-beta2 glycoprotein 1 (anti-β2gp1), anti-cardiolipin antibody (aCL), and/or lupus anticoagulant (LA). The purpose of this study was to evaluate the laboratory profile of LA-positive cases and study its association with various clinical presentations. In this ambispective analytical study over 20 months, LA-positive cases (n = 167) from among 970 cases screened were included. Tests for LA were integrated dilute Russell’s Viper venom time (dRVVT) and silica clotting time (SCT) using screen-confirm procedure with mixing whenever necessary. The clinical profile and other investigations like aCL and anti-β2gp1were noted from records. The sensitivity of dRVVT and SCT for LA positivity were 78.4% and 79.4%, respectively. Based on the clinical presentation the cases were grouped as abortion, thrombosis, systemic lupus erythematosus (SLE) and others. The thrombotic group showed significantly higher (94%) dRVVT positivity, with an odds ratio of 5.56 (95% CI: 1.61 to 19.15). SCT, aCL, or anti-β2gp1 positivity did not show any significant risk association with thrombosis or abortion. SLE- group showed more frequent dual-LA (dRVVT and SCT) positivity. All groups showed higher anti-β2gp1 positivity than aCL. Persistent LA positivity after 12-weeks was more frequent with dual-LA positive (91.67%), double (LA + aCL/anti-β2gp1) and triple (LA + aCL + anti-β2gp1) positive cases (100%). Both dRVVT and SCT had comparable sensitivity. dRVVT positivity was significantly associated with increased thrombotic risk. Persistent LA positivity was more often seen with initially dual, double or triple LA positive cases.

抗磷脂综合征(APS)是一种具有特殊临床特征的自身免疫性疾病,患者体内存在抗磷脂抗体(aPL),如抗β2糖蛋白1(抗β2gp1)、抗心磷脂抗体(aCL)和/或狼疮抗凝物(LA)。本研究的目的是评估 LA 阳性病例的实验室特征,并研究其与各种临床表现的关联。在这项历时 20 个月的前瞻性分析研究中,从 970 例筛查病例中选取了 LA 阳性病例(n = 167)。LA的检测采用综合稀释罗素蝰蛇毒时间(dRVVT)和硅凝血时间(SCT),使用筛选-确认程序,必要时进行混合。临床概况和其他检查(如 aCL 和抗β2gp1)均记录在案。dRVVT 和 SCT 对 LA 阳性的敏感性分别为 78.4% 和 79.4%。根据临床表现,病例被分为流产、血栓形成、系统性红斑狼疮(SLE)和其他类型。血栓形成组的 dRVVT 阳性率明显更高(94%),几率比为 5.56(95% CI:1.61 至 19.15)。SCT、aCL或抗β2gp1阳性与血栓形成或流产没有明显的风险关联。系统性红斑狼疮组的双LA(dRVVT和SCT)阳性率更高。所有组别抗β2gp1阳性率均高于aCL组。12周后LA持续阳性的病例中,双LA阳性(91.67%)、双(LA + aCL/抗-β2gp1)和三(LA + aCL + 抗-β2gp1)阳性病例(100%)更为常见。dRVVT 和 SCT 的敏感性相当。持续的 LA 阳性多见于最初的双 LA、双 LA 或三 LA 阳性病例。
{"title":"Laboratory Profile of Lupus Anticoagulant Positive Cases and its Association with Clinical Presentation- Experience from a Tertiary Care Centre in Southern India","authors":"Pranav Raghuram, Mithraa Devi Sekar, Lokeshwari Srinivasan, Prabhu Manivannan, Debdatta Basu, Rakhee Kar","doi":"10.1007/s12288-024-01851-6","DOIUrl":"https://doi.org/10.1007/s12288-024-01851-6","url":null,"abstract":"<p>Antiphospholipid syndrome (APS) is an autoimmune disease with specific clinical features and the presence of antiphospholipid antibodies (aPL) like anti-beta2 glycoprotein 1 (anti-β2gp1), anti-cardiolipin antibody (aCL), and/or lupus anticoagulant (LA). The purpose of this study was to evaluate the laboratory profile of LA-positive cases and study its association with various clinical presentations. In this ambispective analytical study over 20 months, LA-positive cases (<i>n</i> = 167) from among 970 cases screened were included. Tests for LA were integrated dilute Russell’s Viper venom time (dRVVT) and silica clotting time (SCT) using screen-confirm procedure with mixing whenever necessary. The clinical profile and other investigations like aCL and anti-β2gp1were noted from records. The sensitivity of dRVVT and SCT for LA positivity were 78.4% and 79.4%, respectively. Based on the clinical presentation the cases were grouped as abortion, thrombosis, systemic lupus erythematosus (SLE) and others. The thrombotic group showed significantly higher (94%) dRVVT positivity, with an odds ratio of 5.56 (95% CI: 1.61 to 19.15). SCT, aCL, or anti-β2gp1 positivity did not show any significant risk association with thrombosis or abortion. SLE- group showed more frequent dual-LA (dRVVT and SCT) positivity. All groups showed higher anti-β2gp1 positivity than aCL. Persistent LA positivity after 12-weeks was more frequent with dual-LA positive (91.67%), double (LA + aCL/anti-β2gp1) and triple (LA + aCL + anti-β2gp1) positive cases (100%). Both dRVVT and SCT had comparable sensitivity. dRVVT positivity was significantly associated with increased thrombotic risk. Persistent LA positivity was more often seen with initially dual, double or triple LA positive cases.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"17 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monocytic Blast Crisis in Chronic Myeloid Leukemia and Its Clinical Relevance in the Era of TKIs 慢性髓性白血病中的单核细胞暴发性危机及其在 TKIs 时代的临床意义
IF 0.9 4区 医学 Pub Date : 2024-08-29 DOI: 10.1007/s12288-024-01854-3
Shuchismita, Iffat Jamal, Vijayanand Choudhary
{"title":"Monocytic Blast Crisis in Chronic Myeloid Leukemia and Its Clinical Relevance in the Era of TKIs","authors":"Shuchismita, Iffat Jamal, Vijayanand Choudhary","doi":"10.1007/s12288-024-01854-3","DOIUrl":"https://doi.org/10.1007/s12288-024-01854-3","url":null,"abstract":"","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"15 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisiting the Real-World Prognosis of Intensive Chemotherapy in Elderly Acute Myeloid Leukemia Patients: A Retrospective Analysis from Tokyo 重新审视老年急性髓性白血病患者强化化疗的实际预后:来自东京的回顾性分析
IF 0.9 4区 医学 Pub Date : 2024-08-29 DOI: 10.1007/s12288-024-01852-5
Takeshi Hagino, Reina Saga, Hiroko Hidai, Hisashi Tsutsumi, Hideki Akiyama, Yoshiro Murai, Mayumi Mori, Sayuri Motomura

We investigated whether reduced intensity-chemotherapy (IC) is associated with decreased toxicity and longer overall survival (OS) in elderly AML patients. Age-dependent dose-reduced IC was administered to 110 AML patients between 2004 and 2021. We assessed myelosuppressive toxicity, clinical efficacy, and safety of our regimen using the depth index (D-index). Patients of 66–79 years of age (younger elderly [YE], n = 52) and ≥ 80 years (older elderly [OE], n = 19) were compared to a control group of patients of ≤ 65 years of age (n = 39). Although no significant differences were observed in the number of days with neutrophil count < 500/µl, the D-index, or the onset of sepsis among the groups, OS significantly differed (median OS: control, 578 days [317 days-NA]; YE, 281 days [158–515 days]; OE, 185 days [72–373 days]; p = 0.0001). IC for elderly AML patients achieved negative treatment outcomes despite a reduction in myelosuppressive toxicity, with no data beyond a median OS of 14.7 months for Azacytidine + Venetoclax therapy in a phase 3 VIALE-A trial. Although the findings were negative, the present results provide insights into appropriate IC regimens for elderly AML patients in the future.

我们研究了降低化疗强度(IC)是否会降低老年 AML 患者的毒性并延长其总生存期(OS)。2004 年至 2021 年间,我们对 110 名急性髓细胞白血病患者进行了剂量依赖性减低的 IC 治疗。我们使用深度指数(D-index)评估了骨髓抑制毒性、临床疗效和治疗方案的安全性。我们将 66-79 岁(年轻老年人 [YE],n = 52)和≥ 80 岁(老年老年人 [OE],n = 19)的患者与年龄≤ 65 岁的对照组患者(n = 39)进行了比较。虽然各组间中性粒细胞计数< 500/µl的天数、D指数或脓毒症发病时间无明显差异,但OS却有显著不同(中位OS:对照组,578天[317天-NA];YE组,281天[158-515天];OE组,185天[72-373天];P = 0.0001)。针对老年 AML 患者的 IC 治疗尽管降低了骨髓抑制毒性,但治疗效果并不理想,在一项 VIALE-A 3 期试验中,Azacytidine + Venetoclax 治疗的中位 OS 为 14.7 个月,除此之外没有其他数据。虽然研究结果是负面的,但本研究结果为今后老年 AML 患者采用合适的 IC 治疗方案提供了启示。
{"title":"Revisiting the Real-World Prognosis of Intensive Chemotherapy in Elderly Acute Myeloid Leukemia Patients: A Retrospective Analysis from Tokyo","authors":"Takeshi Hagino, Reina Saga, Hiroko Hidai, Hisashi Tsutsumi, Hideki Akiyama, Yoshiro Murai, Mayumi Mori, Sayuri Motomura","doi":"10.1007/s12288-024-01852-5","DOIUrl":"https://doi.org/10.1007/s12288-024-01852-5","url":null,"abstract":"<p>We investigated whether reduced intensity-chemotherapy (IC) is associated with decreased toxicity and longer overall survival (OS) in elderly AML patients. Age-dependent dose-reduced IC was administered to 110 AML patients between 2004 and 2021. We assessed myelosuppressive toxicity, clinical efficacy, and safety of our regimen using the depth index (D-index). Patients of 66–79 years of age (younger elderly [YE], n = 52) and ≥ 80 years (older elderly [OE], n = 19) were compared to a control group of patients of ≤ 65 years of age (n = 39). Although no significant differences were observed in the number of days with neutrophil count &lt; 500/µl, the D-index, or the onset of sepsis among the groups, OS significantly differed (median OS: control, 578 days [317 days-NA]; YE, 281 days [158–515 days]; OE, 185 days [72–373 days]; <i>p</i> = 0.0001). IC for elderly AML patients achieved negative treatment outcomes despite a reduction in myelosuppressive toxicity, with no data beyond a median OS of 14.7 months for Azacytidine + Venetoclax therapy in a phase 3 VIALE-A trial. Although the findings were negative, the present results provide insights into appropriate IC regimens for elderly AML patients in the future.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"2 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Cold Agglutinin Syndrome in the Post-COVID19 Era 后 COVID19 时代的小儿冷凝集素综合征
IF 0.9 4区 医学 Pub Date : 2024-08-28 DOI: 10.1007/s12288-024-01835-6
Jared Durnford, Ming Wei Lee, Rajat Bhattacharyya, Prasad Iyer

Purpose: This case series describes an increase in the incidence of cold agglutinin syndrome (CAS) in children in Singapore following relaxation of COVID-19-related non-pharmacological interventions (NPIs). Methods: Clinical data of patients diagnosed with CAS from November 2022 to October 2023 following the relaxation of NPIs in October 2022 were collected retrospectively. Data on the number of CAS cases diagnosed before the pandemic (2018–2019) and during the pandemic (January 2020-October 2022) were collected. Results: Thirteen patients were diagnosed with CAS from November 2022 to October 2023, as compared to zero cases diagnosed during the COVID-19 pandemic. There were also more cases than before the pandemic (one case in 2018 and three cases in 2019). The median age of the 13 patients was 4.6 years (range 1.8–12 years). The most commonly detected virus was rhinovirus/enterovirus (54%). Nine children required red cell transfusions. Five patients received corticosteroids. Conclusion: An increase in the number of pediatric CAS cases has been observed since the COVID-19 pandemic. This may be due to an overall increase in viral infections due to the immunity debt from COVID-19 related NPIs. Another possible explanation is the “hygienist theory, ” which postulates a causal relationship between the decline in infections and increase in immunological disorders.

目的:本病例系列描述了新加坡儿童在放宽与 COVID-19 相关的非药物干预(NPI)后,冷凝集素综合征(CAS)发病率的增加情况。研究方法回顾性收集2022年10月放宽NPI后,2022年11月至2023年10月期间诊断为CAS患者的临床数据。收集了大流行前(2018-2019 年)和大流行期间(2020 年 1 月-2022 年 10 月)确诊的 CAS 病例数数据。结果:2022年11月至2023年10月期间,13名患者被确诊为CAS,而在COVID-19大流行期间确诊的病例为零。病例数也比大流行前多(2018 年 1 例,2019 年 3 例)。13 名患者的中位年龄为 4.6 岁(1.8-12 岁不等)。最常检测到的病毒是鼻病毒/肠病毒(54%)。九名患儿需要输注红细胞。五名患者接受了皮质类固醇激素治疗。结论自 COVID-19 大流行以来,儿童 CAS 病例数量有所增加。这可能是由于与 COVID-19 相关的非典型肺炎造成的免疫力下降导致病毒感染的总体增加。另一种可能的解释是 "卫生学家理论",该理论认为感染减少与免疫紊乱增加之间存在因果关系。
{"title":"Pediatric Cold Agglutinin Syndrome in the Post-COVID19 Era","authors":"Jared Durnford, Ming Wei Lee, Rajat Bhattacharyya, Prasad Iyer","doi":"10.1007/s12288-024-01835-6","DOIUrl":"https://doi.org/10.1007/s12288-024-01835-6","url":null,"abstract":"<p>Purpose: This case series describes an increase in the incidence of cold agglutinin syndrome (CAS) in children in Singapore following relaxation of COVID-19-related non-pharmacological interventions (NPIs). Methods: Clinical data of patients diagnosed with CAS from November 2022 to October 2023 following the relaxation of NPIs in October 2022 were collected retrospectively. Data on the number of CAS cases diagnosed before the pandemic (2018–2019) and during the pandemic (January 2020-October 2022) were collected. Results: Thirteen patients were diagnosed with CAS from November 2022 to October 2023, as compared to zero cases diagnosed during the COVID-19 pandemic. There were also more cases than before the pandemic (one case in 2018 and three cases in 2019). The median age of the 13 patients was 4.6 years (range 1.8–12 years). The most commonly detected virus was rhinovirus/enterovirus (54%). Nine children required red cell transfusions. Five patients received corticosteroids. Conclusion: An increase in the number of pediatric CAS cases has been observed since the COVID-19 pandemic. This may be due to an overall increase in viral infections due to the immunity debt from COVID-19 related NPIs. Another possible explanation is the “hygienist theory, ” which postulates a causal relationship between the decline in infections and increase in immunological disorders.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"3 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Imatinib Mesylate on the Ovarian Reserves of Female Patients with Chronic Myeloid Leukaemia 甲磺酸伊马替尼对慢性髓性白血病女性患者卵巢储备功能的影响
IF 0.9 4区 医学 Pub Date : 2024-08-27 DOI: 10.1007/s12288-024-01846-3
Tanya Satija, Vanita Suri, Aashima Arora, Nalini Gupta, Naresh Sachdeva, Arihant Jain, Pankaj Malhotra
<p>Purpose: Imatinib mesylate (IM) has transformed the treatment of chronic myeloid leukaemia (CML). The improved life expectancy of CML patients has led to increased attention to the adverse effects of the drug. There are conflicting reports of the impact of IM on the female reproductive system. A few studies suggested that IM may reduce ovarian reserve and cause menstrual irregularities in female patients. We systematically looked at the effect of IM on the female reproductive system in a case-control study. Methodology: The study was conducted in the outpatient clinics of the Department of Obstetrics and Gynaecology and the Haematology Clinic. We enrolled 44 patients with CML chronic phase (CML-CP) who had been taking IM for at least one year and 24 patients who had been newly diagnosed with CML CP but had not yet started treatment with IM. CML CP was diagnosed through bone marrow examination and the detection of BCR-ABL transcripts via polymerase chain reaction (PCR). We administered a structured questionnaire to obtain demographic information, menstrual and sexual history, and age at menopause from all patients who had not yet reached menopause at the time of recruitment. We evaluated the effects of IM on menstrual pattern and ovarian reserve using quantitative and qualitative measures, including menstrual cycle characteristics, antral follicle count (AFC), and Anti-Mullerian hormone (AMH) levels in both groups of patients. A transvaginal ultrasound was performed between days 2–5 of the menstrual cycle to determine AFC. AMH levels were tested in the serum of menstruating patients among both cases (<i>n</i> = 30) and controls (<i>n</i> = 19). These variables were compared between both groups to determine the association between IM use and ovarian reserve. Results: The median age of the cases was 40.5 years (range: 22.0–71.0), while the control population had a median age of 35.5 years (range: 22.0–60.0). The median duration of IM therapy was 2.5 years, with a range of 1–15 years. After excluding patients who had already reached menopause at the time of recruitment, there was no significant difference in AMH levels (3.00 ± 5.43 ng/mL in cases versus 4.38 ± 4.69 ng/mL in controls; <i>p</i> = 0.154) or AFC (4.97 ± 3.31 in cases versus 6.16 ± 3.50 in controls; <i>p</i> = 0.219). Similarly, the two groups had no significant difference in menstrual cycle characteristics. However, the age at menopause was significantly lower in patients taking IM for at least one year (except for three women who had already reached menopause before starting imatinib), compared to the control group (41.00 ± 3.46 years versus 47.80 ± 2.49 years, <i>p</i> = 0.006). Conclusion: The study found no significant differences in ovarian reserve parameters, as measured by menstrual cycle characteristics, AMH levels, and antral follicle count, between CML patients receiving IM therapy and newly diagnosed patients who had not yet started treatment. However, our findings highligh
目的:甲磺酸伊马替尼(IM)改变了慢性髓性白血病(CML)的治疗方法。随着 CML 患者预期寿命的延长,人们越来越关注该药物的不良反应。关于 IM 对女性生殖系统的影响,有相互矛盾的报道。一些研究表明,IM 可能会降低女性患者的卵巢储备功能并导致月经不调。我们在一项病例对照研究中系统地考察了 IM 对女性生殖系统的影响。研究方法研究在妇产科和血液科门诊进行。我们招募了 44 名已服用 IM 至少一年的 CML 慢性期(CML-CP)患者和 24 名新诊断为 CML CP 但尚未开始接受 IM 治疗的患者。CML CP 是通过骨髓检查和聚合酶链反应(PCR)检测 BCR-ABL 转录物确诊的。我们发放了一份结构化问卷,以了解所有招募时尚未绝经的患者的人口统计学信息、月经史和性史以及绝经年龄。我们采用定量和定性方法评估了IM对月经模式和卵巢储备功能的影响,包括两组患者的月经周期特征、前卵泡计数(AFC)和抗穆勒氏管激素(AMH)水平。在月经周期的第 2-5 天进行经阴道超声波检查,以确定 AFC。对月经期患者血清中的 AMH 水平进行检测,包括病例组(30 人)和对照组(19 人)。对两组患者的这些变量进行比较,以确定使用 IM 与卵巢储备功能之间的关系。研究结果病例的中位年龄为 40.5 岁(范围:22.0-71.0),而对照组的中位年龄为 35.5 岁(范围:22.0-60.0)。接受 IM 治疗的时间中位数为 2.5 年,范围在 1-15 年之间。在排除了招募时已经绝经的患者后,两组患者的 AMH 水平(病例为 3.00 ± 5.43 ng/mL,对照组为 4.38 ± 4.69 ng/mL;P = 0.154)或 AFC 水平(病例为 4.97 ± 3.31,对照组为 6.16 ± 3.50;P = 0.219)无显著差异。同样,两组患者的月经周期特征也无明显差异。然而,与对照组相比,服用 IM 至少一年的患者绝经年龄明显较低(除了 3 名妇女在开始服用伊马替尼前已经绝经)(41.00 ± 3.46 岁对 47.80 ± 2.49 岁,p = 0.006)。结论研究发现,接受 IM 治疗的 CML 患者与尚未开始治疗的新确诊患者在卵巢储备参数(以月经周期特征、AMH 水平和前卵泡计数衡量)方面无明显差异。然而,我们的研究结果突显了接受 IM 治疗的患者可能存在早期先天性绝经的风险,这表明有必要通过更大规模的研究进行进一步调查。
{"title":"Effect of Imatinib Mesylate on the Ovarian Reserves of Female Patients with Chronic Myeloid Leukaemia","authors":"Tanya Satija, Vanita Suri, Aashima Arora, Nalini Gupta, Naresh Sachdeva, Arihant Jain, Pankaj Malhotra","doi":"10.1007/s12288-024-01846-3","DOIUrl":"https://doi.org/10.1007/s12288-024-01846-3","url":null,"abstract":"&lt;p&gt;Purpose: Imatinib mesylate (IM) has transformed the treatment of chronic myeloid leukaemia (CML). The improved life expectancy of CML patients has led to increased attention to the adverse effects of the drug. There are conflicting reports of the impact of IM on the female reproductive system. A few studies suggested that IM may reduce ovarian reserve and cause menstrual irregularities in female patients. We systematically looked at the effect of IM on the female reproductive system in a case-control study. Methodology: The study was conducted in the outpatient clinics of the Department of Obstetrics and Gynaecology and the Haematology Clinic. We enrolled 44 patients with CML chronic phase (CML-CP) who had been taking IM for at least one year and 24 patients who had been newly diagnosed with CML CP but had not yet started treatment with IM. CML CP was diagnosed through bone marrow examination and the detection of BCR-ABL transcripts via polymerase chain reaction (PCR). We administered a structured questionnaire to obtain demographic information, menstrual and sexual history, and age at menopause from all patients who had not yet reached menopause at the time of recruitment. We evaluated the effects of IM on menstrual pattern and ovarian reserve using quantitative and qualitative measures, including menstrual cycle characteristics, antral follicle count (AFC), and Anti-Mullerian hormone (AMH) levels in both groups of patients. A transvaginal ultrasound was performed between days 2–5 of the menstrual cycle to determine AFC. AMH levels were tested in the serum of menstruating patients among both cases (&lt;i&gt;n&lt;/i&gt; = 30) and controls (&lt;i&gt;n&lt;/i&gt; = 19). These variables were compared between both groups to determine the association between IM use and ovarian reserve. Results: The median age of the cases was 40.5 years (range: 22.0–71.0), while the control population had a median age of 35.5 years (range: 22.0–60.0). The median duration of IM therapy was 2.5 years, with a range of 1–15 years. After excluding patients who had already reached menopause at the time of recruitment, there was no significant difference in AMH levels (3.00 ± 5.43 ng/mL in cases versus 4.38 ± 4.69 ng/mL in controls; &lt;i&gt;p&lt;/i&gt; = 0.154) or AFC (4.97 ± 3.31 in cases versus 6.16 ± 3.50 in controls; &lt;i&gt;p&lt;/i&gt; = 0.219). Similarly, the two groups had no significant difference in menstrual cycle characteristics. However, the age at menopause was significantly lower in patients taking IM for at least one year (except for three women who had already reached menopause before starting imatinib), compared to the control group (41.00 ± 3.46 years versus 47.80 ± 2.49 years, &lt;i&gt;p&lt;/i&gt; = 0.006). Conclusion: The study found no significant differences in ovarian reserve parameters, as measured by menstrual cycle characteristics, AMH levels, and antral follicle count, between CML patients receiving IM therapy and newly diagnosed patients who had not yet started treatment. However, our findings highligh","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"24 1","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142190744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Hematology and Blood Transfusion
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1